2 Reasons to Buy the Stock:
- Ibrance drug to drive top-line growth
- High possibilities of the stock thriving in the near future
Summary:
This summary focuses solely on highlighting Pfizer’s drug Ibrance and how it is changing the landscape of treating breast cancer. Breast cancer is currently one of the most lethal diseases in America. Sadly, according to breastcancer.org, around 12% of women will 
acquire breast cancer in their lifetime. In 2015, there were 231,840 women who were diagnosed and of those, 40,290 died. In 2016, these numbers are increasing at a rate of 6.4%, with a .4% rise in death. On February 3, 2015, the Food and Drug Administration also known as the “FDA” granted Ibrance, one of Pfizer’s leading breast cancer drugs. It has been proven that patients who were given Ibrance live on average 20.2 months longer deprived of breast cancer and without Ibrance, 10.2 months.
Ibrance already has a good reputation as it has been recommended by 5,000 physicians and is currently being taken by over 20,000 patients. The feedback has been tremendous and has a huge effect on patient’s quality of life. At this, Ibrance is booming in Europe, so much so that it is apparent this particular drug is what is going to be key in Pfizer’s growth.
jufiberclub.wordpress.com 